HIGH LEVELS OF PROINFLAMMATORY CYTOKINES TUMOR NECROSIS FACTOR ALPHA, INTERLEUKIN 1β AND NTERLEUKIN 6 IN BONE MARROW AND PERIPHERAL BLOOD OF BREAST CANCER PATIENTS AS PREDICTORS OF RELAPSE

N. I. Semesiuk, A. V. Zhylchuk, N. O. Bezdenezhnykh, O. O. Lykhova, A. L. Vorontsova, V. E. Zhylchuk, Yu. I. Kudryavets


DOI: http://dx.doi.org/10.30970/sbi.0802.361

Abstract


Breast cancer provides a typical example of an inflammation-linked malignant disease. The inflammatory components present in the tumor microenvironment contribute to the further progression of the disease. The present study was conducted to evaluate the correlation between levels of proinflammation cytokines tumor necrosis factor α, interleukin 1β, interleukin 6, C-reactive protein and tumor recurrence in breast cancer patients. Seventy two breast cancer patients with histologically proven diagnosis and 15 healthy donors were enrolled into study. Thirty one patients with progression of the disease and 41 patients with clinical stabilization (conditional remission) were included to “progression” and “remission” groups respectively. This division of breast cancer patients was made during the 3 years study. The levels of proinflammation cytokines – tumor necrosis factor α, interleukin 1β, interleukin 6 and C-reactive protein were revealed. This cytokines in bone marrow and peripheral blood act as a specific microenvironment and was found that the elevated levels of this cytokines were strongly associated with progression of breast cancer. The data showed that most prominent predictive markers of tumor recurrence are high levels of indicated cytokines in combination with other markers (C-reactive protein; disseminated tumor cells in bone marrow). Determination of the high levels of tumor necrosis factor, interleukin 1β, interleukin 6 in bone marrow and peripheral blood of breast cancer patients are important to establish the features of bone marrow microenvironment for prediction of metastasis and correction antitumor therapy.


Keywords


breast cancer, proinflammatory cytokines, bone marrow, peripheral blood, disseminated tumor cells

Full Text:

PDF

References


1. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001; 357: 539-545.
https://doi.org/10.1016/S0140-6736(00)04046-0

2. Ben-Baruch A. Host microenvironment in breast cancer development. Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res, 2003; 5: 31-36.
https://doi.org/10.1186/bcr554
PMid:12559043 PMCid:PMC154133

3. Colotta F, Allavena P., Sica A. et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 2009; 30(7): 1073-1081.
https://doi.org/10.1093/carcin/bgp127
PMid:19468060

4. Crowther M., Brown N.J., Bishop E.T. et al. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J. Leuk Biol, 2001; 70: 478-490.

5. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer, 2004; 4: 11-22.
https://doi.org/10.1038/nrc1252
PMid:14708024

6. Geng Y., Chandrasekaran S., Hsu J-W. et al. Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. Plos One, 2013; 8: e54959.
https://doi.org/10.1371/journal.pone.0054959
PMid:23372803 PMCid:PMC3553003

7. Kozłowski L., Zakrzewska I., Tokajuk P. et al. Concentration of interleukin 6 (IL-6), interleukin 8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Ann Academ. Med. Bialostocensis, 2003; 48: 82-84.

8. Kudryavets Yu.I. Interferon and tumor necrosis factor as modifiers of metastasis of malignant tumors. Abstract of doctoral dissertation. Kyiv, 1999. 36 p. (In Ukrainian)

9. Kudryavets Yu.I. Modifying effect of recombinant tumor necrosis factor in the metastatic potential of tumor cells. Exp Oncol,1990; 12: 47-50. (In Russian)

10. Lai R., O'Brien S., MaushouriT. et al. Prognostic value of plasma Interleukin 6 levels in patients with chronic lymphocytic leukemia. Cancer, 2002; 95(5): 1071-1075.
https://doi.org/10.1002/cncr.10772
PMid:12209693

11. Lang B.A., Silverman E.D., Laxer R.M. et al. Spontaneuos tumor necrosis factor production in Kawasaki disease. J. Pediatrics, 1989; 115: 939-943.
https://doi.org/10.1016/S0022-3476(89)80746-2

12. Leek R.D., Lewis C.E., Whithouse R. et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res, 1996; 56: 4625-4629.

13. Leibovich-Rivkin T., Liubomirski Y., Bernstein B. et al. Tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures. Neoplasia, 2013; 15: 1330-1346.
https://doi.org/10.1593/neo.131688
PMid:24403855 PMCid:PMC3884524

14. Lu H., OuyangW., Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res, 2006; 4: 221-233.
https://doi.org/10.1158/1541-7786.MCR-05-0261
PMid:16603636

15. Okada F. Inflammation and free radicals in tumor development and progression. Redox Rep 2002; 7: 357-368.
https://doi.org/10.1179/135100002125001135
PMid:12625943

16. Semesiuk N.I., Zhylchuk A.V., Bezdenezhnykh N.O. et al. Disseminated tumor cells and enhanced level of some cytokines in bone marrow and peripheral blood of breast cancer patients as predictive factors of tumor progression. Exp. Oncol, 2013; 35(4): 295-302.

17. Semesiuk N.I., Zhylchuk A.V., Bezdenezhnykh N.O. et al.Tumor necrosis factor in peripheral blood and bone marrow of breast cancer patients as a marker of the tumor progression. Oncologiya, 2012; 4: 293-297. (In Ukrainian)

18. Sirotkovic-Skerlev M., Kulic A., Bradic L. et al. Protumor effects of proinflammatory mediators in breast cancer. Period. Biolog, 2012; 114(4): 489-496.

19. Soria G., Ofri-Sharak M., Haas I. et al. Inflammatory mediators in breast cancer: Coordinated expression of TNF-α and IL-1β with CCL2 and CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer, 2011; 11:130-149.
https://doi.org/10.1186/1471-2407-11-130
PMid:21486440 PMCid:PMC3095565

20. Sullivan N.J. Interleukin 6 in the breast tumor microenvironment: Breast Cancer-Focusing Tumor Microenvironment, Stem cells and Metastasis. M Gunduz (ed.), 2011; 165-75.

21. Sullivan N.J., Sasser A.K., Axe A.E. et al. Interleukin 6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene, 2009; 28: 2940-2947.
https://doi.org/10.1038/onc.2009.180
PMid:19581928 PMCid:PMC5576031

22. Sullivan N.J. Interleukin 6 as a potential mediator of breast cancer progression and non-melanoma skin carcinogenesis. Dissertation. 2009, 101 p.

23. Tawara K., Oxford J.T., Jorcyk C.L. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag. Res, 2011; 3:177-189.
https://doi.org/10.2147/CMAR.S18101
PMid:21625400 PMCid:PMC3101113

24. van Horssen R., Hagen T.L., Eggermont A.M. TNF-alpha in cancer treatment: molecular insight, antitumor effects and clinical utility. Oncologist, 2006; 11: 397-408.
https://doi.org/10.1634/theoncologist.11-4-397
PMid:16614236

25. Vega-Avila E., Pugsley K.M. An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc. West Pharmacol. Soc, 2011; 54: 10-14.

26. Waterston A., Bower M. TNF and cancer: good and bad? Cancer Ther, 2004; 2: 131-148.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2014 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.